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ABSTRACT
Objective: To evaluate the relationship between bio-
marker levels and disease activity and the spinal
inflammation detected by magnetic resonance imaging
(MRI) in patients with ankylosing spondylitis (AS).
Methods: Patients with AS were randomly assigned in a
3:8 ratio to receive infusions of placebo or 5 mg/kg
infliximab at weeks 0, 2, 6, 12 and 18. Sera were
collected for biomarker analysis at weeks 0, 2 and 24 and
were analysed for levels of interleukin-6 (IL-6), vascular
endothelial growth factor (VEGF) and C-reactive protein
(CRP). Bath Ankylosing Spondylitis Disease Activity Index
(BASDAI) scores and pre- and post-gadolinium T1 and
short t inversion recovery MRIs were collected at
baseline and week 24.
Results: Significantly greater reductions in IL-6, VEGF and
CRP were observed at weeks 2 and 24 in the infliximab
group compared with the placebo group (all p,0.001).
Baseline IL-6 levels .7.38 pg/ml and CRP levels
.1.5 mg/dl were associated with increased rates of
clinical response after 24 weeks. Multiple regression
analyses showed that reductions from baseline to week 2
in IL-6, but not CRP or VEGF, were significantly associated
with reductions in MRI activity and BASDAI scores from
baseline to week 24 in the infliximab group (p,0.001).
Conclusions: Significant reductions in IL-6, VEGF and
CRP were observed with infliximab compared with
placebo. High levels of baseline IL-6 and CRP were
associated with clinical response after infliximab treat-
ment. Early reductions in IL-6 were significantly asso-
ciated with improvements in disease activity and the
spinal inflammation detected by MRI.
Ankylosing spondylitis (AS) is associated with
persistent inflammation of the sacroiliac joints
and spine, which can lead to bone erosions,
syndesmophytes or complete ankylosis of the
spine. There is evidence that the inflammation in
AS is at least partly mediated by tumour necrosis
factor (TNF)-a and interleukin (IL)-6, as high levels
of these cytokines have been found in biopsies
from the sacroiliac joints of patients with AS.
12
Elevated serum levels of TNF-a and vascular
endothelial growth factor (VEGF) have been
shown to be correlated with disease activity and
C-reactive protein (CRP) levels.
34
VEGF is an important regulator of angiogenesis,
which is key to the inflammatory process. Polymor-
phisms in the VEGF genes were reported to be asso-
ciated with disease severity in patients with AS.
56
IL-6 is a multifunctional cytokine that regulates
immune response, haematopoiesis, acute phase
response and inflammation. Dysregulation of IL-6
production is implicated in the pathology of several
disease processes,
7–9 and increased IL-6 levels have
been associated with rheumatoid arthritis, sys-
temic-onset juvenile chronic arthritis, osteoporosis
and psoriasis.
10–12 IL-6 is critically involved in
experimentally induced autoimmune disease, such
as antigen-induced arthritis, and experimental
allergic encephalomyelitis.
13 14 Collectively, these
data from both clinical studies and animal models
suggest that IL-6 plays a critical role in the
pathogenesis of immune-mediated diseases,
15 sup-
porting the face validity of the use of biomarkers to
predict treatment response.
The course of spinal inflammation associated
with AS can be demonstrated by magnetic
resonance imaging (MRI).
16 17 While a significant
reduction in spinal inflammation has been shown
with MRI after treatment with anti-TNF-a
agents,
18–21 a direct link between clinical disease
activity and spinal inflammation as seen on MRI
and osteoproliferative changes has not been well
characterised.
In the current study, biomarkers known to be
important in the inflammatory and angiogenic
processes that occur in AS were selected for
evaluation over time. The first aim of this study
was to determine whether treatment with inflix-
imab modulates specific biomarkers in patients
with AS, and when such modulation may occur.
The second aim was to evaluate associations
between changes in biomarker levels and disease
activity and inflammation detected by MRI.
MATERIALS AND METHODS
The details of the ASSERT (Ankylosing Spondylitis
Study for the Evaluation of Recombinant
Infliximab Therapy) study have been published
previously.
22 Sera from patients who received
placebo or 5 mg/kg infliximab were collected for
biomarker analysis at weeks 0, 2, and 24. IL-6,
VEGF and interferon (IFN)-c were evaluated
as markers of inflammation. Enzyme-linked
immunoabsorbent assay kits for IL-6 and VEGF
were purchased from R&D Systems (Minneapolis,
MN, USA), and those for IFN-c were purchased
from Biosource, Europe S.A. The Tina-quant
kit from Roche (Indianapolis, IN, USA) was
used to determine CRP levels. All assays were
validated by scientists at Clinical Pharmacology
and Experimental Medicine, Centocor Research
and Development, Inc. before use on study
samples. Biomarker levels that were below the
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undetectable.
Disease activity was assessed using the Bath Ankylosing
Spondylitis Disease Activity Index (BASDAI), which has a
possible score of 0–10 with a higher score indicating greater
disease activity.
23 Clinical response was assessed by determining
the number of patients who achieved a 50% improvement in the
BASDAI score (BASDAI 50) and the number of patients who
achieved 20% improvement in the ASsessment in Ankylosing
Spondylitis working group criteria (ASAS 20).
24
MRI was conducted at baseline and week 24 as previously
reported.
20 Pre- and post-gadolinium T1 and short t inversion
recovery magnetic resonance images of the spine were acquired
at baseline and week 24. The activity score for each vertebral
unit ranged from 0 to 6, and the total activity score for the spine
ranged from 0 to 138 (23 vertebral units from C2 to S1).
19 25–27
Statistical analyses
To validate the use of biomarkers in predicting the treatment
response in patients with AS who received infliximab, we
evaluated the face validity, discriminant capacity, predictive
validity and sensitivity to change. Face validity was determined
by assessing the relationship between biomarker levels and
disease activity at baseline. Discriminant capacity and sensitiv-
ity to change was assessed by demonstrating the effect of
infliximab treatment on biomarker levels relative to placebo
after 2 and 24 weeks of follow-up. Predictive validity was
evaluated by determining the association between changes from
baseline in disease activity (BASDAI and MRI scores) and
biomarker levels at baseline, week 2 and week 24.
The median percentage change from baseline for each
biomarker was determined at weeks 2 and 24. Statistical
comparisons were made between the placebo and infliximab
groups using an analysis of variance on the van der Waerden
scores. Biomarker data for patients with sample baseline values
less than the LLOQ were excluded from analyses.
Univariate Spearman Rank correlations were computed to
determine the relationship between baseline levels of IL-6, VEGF
and CRP. Correlation analyses were also used to examine
relationships between (1) the change from baseline to week 24
in MRI activity score and the biomarker levels (baseline and
changes from baseline to week 2 and week 24), and (2) the
associations between change from baseline to week 24 in
BASDAI and biomarker levels (baseline and changes from
baseline to week 2 and week 24).
To further characterise the relationship between biomarker
levels, disease activity and inflammation at baseline, patients
were categorised into quantiles of baseline CRP and IL-6, and
descriptive statistics of baseline MRI activity and BASDAI
scores were calculated for each category. For CRP, patients were
divided into tertile categories (,0.9 mg/dl, >0.9 and ,2.4 mg/
dl, or >2.4 mg/dl) because all patients had detectable levels of
CRP at baseline (table 1). Nearly half of the patients were
assigned the same baseline IL-6 value (3.13 pg/ml, which was
one-half of the LLOQ of 6.25 pg/ml) because their levels were
below the LLOQ (table 1). Therefore, patients were divided into
categories of IL-6 levels based on the median IL-6 value at
baseline (,7.38 pg/ml or .7.38 pg/ml). The percentage of
patients who achieved an ASAS 20 or BASDAI 50 response at
week 24 was also calculated for each category of baseline CRP
and IL-6.
A multiple linear regression analysis was performed to explore
baseline levels of IL-6, CRP and VEGF as potential indicators of
the change from baseline to week 24 in MRI activity scores and
the change from baseline to week 24 in BASDAI scores. Similar
analyses were performed to evaluate the percentage changes in
these biomarkers from baseline to week 2 and from baseline to
week 24.
Statistical analyses were performed using the SAS system,
version 8.2 (SAS Institute, Cary, NC, USA). P-values have been
provided for exploratory purposes and were not adjusted for
multiplicity. Statistical tests were two-sided, and p,0.05 was
considered significant.
RESULTS
Baseline characteristics and biomarker levels
The baseline characteristics of patients in the ASSERT trial are
summarised in table 1. The study population was typical of
patients with well-established, active AS. As reported pre-
viously,
22 the majority of the patients in ASSERT were men,
most of whom tested positive for the HLA-B27 allele. The
median assessment of average morning stiffness on a visual
analogue scale was 7.0 in the placebo group and 7.3 in the
infliximab group. Although there appeared to be a disparity
between the groups in the median disease duration (13.2 years
in the placebo group and 7.7 years in the infliximab group), the
means were similar (11.9 and 10.1 years, respectively).
The treatment groups were also generally comparable for all
biomarkers of inflammation at baseline. The median IL-6 level
in the placebo group (3.1 pg/ml) was lower than that of the
infliximab group (7.7 pg/ml), but the means were comparable
(11.4 vs 13.2, respectively). Approximately half of the patients
had IL-6 levels that were above the LLOQ for the assay (47.8%
and 56.1% of placebo and infliximab groups, respectively). Only
12 patients had IFN-c levels that were above the LLOQ for the
assay (4.8% and 5.5%, respectively).
Correlations between individual biomarker levels at baseline and
after treatment with infliximab or placebo
In all patients, Spearman Rank correlation coefficients among
baseline biomarker levels showed a strong and statistically
significant relationship between IL-6 and CRP levels (0.698,
p,0.001). Moderate correlations between CRP and VEGF
(0.362, p,0.001) and IL-6 and VEGF (0.264, p,0.001) were
also observed.
Correlations among changes in biomarker levels at week 24
were also evaluated. In the infliximab group, there were
significant relationships between change from baseline in IL-6
and CRP (r=0.689, p,0.001), IL-6 and VEGF (r=0.445,
p,0.001), and VEGF and CRP (r=0.565, p,0.001) at week
24. In the placebo group, only a significant correlation between
IL-6 and CRP was observed (r=0.452, p,0.001).
Face validity: baseline biomarker levels and disease activity,
peripheral involvement and extra-articular manifestations
At baseline, Spearman correlation coefficients between BASDAI
scores and IL-6 levels (0.134, p=0.0327) and BASDAI scores and
CRP levels (0.167, p=0.005) were similar, as were those between
MRI activity scores and IL-6 levels (0.240, p=0.0001) and MRI
activity scores and CRP levels (0.282, p,0.0001).
We also evaluated baseline MRI activity and BASDAI scores
for subgroups of baseline IL-6 and CRP (fig 1). Patients with IL-6
levels greater than the median (7.38 pg/ml, hereafter referred to
as patients with elevated IL-6) had significantly greater MRI
activity scores than those with IL-6 levels at or below the
median (p,0.001). Overall, 75.0% of patients with elevated IL-6
had a baseline MRI activity score .1 compared with 56.3% of
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levels .3 times the upper limit of normal (normal range 0–
0.5 mg/dl) had significantly greater MRI activity scores
compared with those with CRP levels (3 times the upper
limit of normal (p,0.001). The trends between baseline IL-6 or
CRP levels and BASDAI scores were similar to those observed
for MRI activity scores; however, the magnitude of the
differences between the medians of the groups was not as great
for BASDAI as it was for the MRI activity scores (p=0.0648 for
IL-6 and p=0.006 for CRP) (fig 1).
Patients with elevated IL-6 levels at baseline were also more
likely to have peripheral joint involvement than those with low
IL-6 levels (50.0% vs. 28.1%, respectively, p,0.001) and had a
greater mean (SD) number of peripheral swollen joints (2.02
(3.44) joints versus 1.20 (3.30) joints, p,0.001). Moreover,
78.9% of patients with elevated IL-6 levels had CRP levels
.3 times the upper limit of normal compared with 17.2% of
patients with low IL-6 levels (p,0.001). The baseline mean (SD)
CRP level for patients with elevated IL-6 levels was 3.79
(3.27) mg/dl compared with 1.04 (0.81) mg/dl for patients with
low IL-6 levels (p,0.001). There were no statistically significant
differences in age, disease duration, baseline inflammation
(visual analogue scale), or the presence of uveitis between
patients with low and high IL-6 levels (data not shown).
Discriminant capacity and sensitivity to change: reduction in
biomarker levels after treatment with infliximab or placebo
Percentage changes in biomarker levels from baseline to week 2
and from baseline to week 24 are shown for infliximab- and
placebo-treated patients in fig 2. Significantly greater reductions
in IL-6, VEGF and CRP levels were observed at both week 2 and
week 24 for patients in the infliximab group compared with the
placebo group (p,0.001). There was no difference between the
treatment groups in the change in IFN-c levels.
Predictive validity: correlations between biomarker levels and
changes in disease activity and spinal inflammation
Univariate correlations between biomarker levels and changes in
MRI activity and BASDAI scores are summarised in table 2. In the
infliximab group, baseline IL-6 and CRP levels were significantly
correlated inversely with changesfrom baseline toweek 24 in MRI
activity scores (p(0.001) and BASDAI scores (p(0.001), with
high baseline IL-6 and CRP levels associated with greater
reductions in the two indices. In addition, percentage changes
from baseline to week 2 and 24 in IL-6, VEGF and CRP levels were
significantly correlated with changes in MRI activity scores
(p,0.05) and BASDAI scores (p(0.001) from baseline to week
24. Thus, decreases from baseline to week 2 and 24 in IL-6, CRP
and VEGF levels were significantly correlated with improvement
in MRI activity and BASDAI scores. Correlations with changes in
IFN-c levels were not evaluated because of the small number of
patients who had detectable IFN-c levels at baseline.
Predictive validity: baseline biomarker levels and ASAS 20 and
BASDAI 50 response
Figure 3 shows the treatment response of patient groups
categorised according to their baseline biomarker levels.
Among patients who received infliximab, a greater percentage
of those with elevated IL-6 at baseline (.7.38 pg/ml) demon-
strated a clinical response as measured by ASAS 20 (A,
p,0.0001) and BASDAI 50 (C, p=0.002) compared with those
with low IL-6. Similarly, a greater percentage of infliximab-
treated patients with CRP .3 times the upper limit of normal
(1.5 mg/dl) achieved an ASAS 20 (B, p,0.001) and BASDAI 50
(D, p=0.002) responses compared with the percentage with
CRP (3 times the upper limit of normal.
Predictive validity: multiple regression associations between
biomarker levels and changes in disease activity and spinal
inflammation
Multiple linear regression analyses were conducted to evaluate
whether one individual marker (IL-6, VEGF and CRP) was more
strongly associated with change in MRI activity or BASDAI
scores from baseline to week 24 (table 3). Early reductions in IL-
6 from baseline to week 2 were significantly associated with
improvement from baseline to week 24 in MRI activity and
BASDAI. Reductions from baseline to week 24 in CRP were
significantly associated with reductions in MRI activity scores
at week 24; however, both baseline levels and the decrease in
CRP from baseline to week 24 were associated with reductions
in BASDAI. Further, reductions in VEGF levels at week 24 were
also significantly associated with change from baseline to week
24 in BASDAI. Thus, in the infliximab group, early decreases in
IL-6 and later decreases in CRP were associated with improvement
Table 1 Baseline characteristics
Assessment
Placebo
n=78
5 mg/kg
Infliximab
n=201
Men, no. (%) 68 (87.2) 157 (78.1)
Disease duration, years
n 76 201
Mean (SD) 11.9 (8.0) 10.1 (8.7)
Median (IQ range) 13.2 (3.7, 17.9) 7.7 (3.3, 14.9)
HLA-B27 positive
n 78 200
No. (%) 69 (88.5) 173 (86.5)
Inflammation (average morning stiffness
on a visual analogue scale 0–10 cm)
n 78 201
Mean (SD) 6.9 (1.9) 6.9 (2.3)
Median (IQ range) 7.0 (5.7, 8.3) 7.3 (5.4, 8.5)
BASDAI score
n 78 201
Mean (SD) 6.2 (1.6) 6.5 (1.5)
Median (IQ range) 6.5 (5.2, 7.1) 6.6 (5.3, 7.6)
C-reactive protein (mg/dl)
n 78 201
No. (%) with values >LLOQ 78 (100) 201 (100)
Mean (SD) 2.4 (2.8) 2.4 (2.7)
Median (IQ range) 1.7 (0.7, 3.3) 1.5 (0.7, 3.2)
Interleukin-6 (pg/ml)
n 67 187
No. (%) with values >LLOQ 32 (47.8) 105 (56.1)
Mean (SD) 11.4 (17.2) 13.2 (20.0)
Median (IQ range) 3.1 (3.1, 14.8) 7.7 (3.1, 14.2)
Vascular endothelial growth factor (pg/ml)
n 75 193
No. (%) with values >LLOQ 75 (100.0) 191 (99.0)
Mean (SD) 556.2 (385.6) 520.4 (361.5)
Median (IQ range) 473.5 (289.5, 738.0) 421.5 (279.9, 664.3)
Interferon-c (pg/ml)
n 62 165
No. (%) with values >LLOQ 3 (4.8) 9 (5.5)
Mean (SD) 0.7 (1.3) 0.6 (0.3)
Median (IQ range) 0.5 (0.5, 0.5) 0.5 (0.5, 0.5)
BASDAI, Bath Ankylosing Spondylitis Disease Activity Index; IQ, interquartile; LLOQ,
lower limit of quantification.
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baseline CRP levels were associated with improvement in BASDAI
scores.
DISCUSSION
The results of this study show that the established efficacy of
infliximab for improving the clinical signs and symptoms of AS
and reducing spinal inflammation demonstrated by MRI
19–21 is
also associated with significant changes in inflammatory
biomarkers. Understanding the utility of specific biomarkers
associated with anti-TNF-a therapy may be particularly
important in AS because the rate of structural changes is rather
slow over time,
28 29 and early identification of patients who will
Figure 1 Baseline magnetic resonance imaging (MRI) activity and
BASDAI (Bath Ankylosing Spondylitis Disease Activity Index) scores for
quantiles of baseline interleukin (IL)-6 and C-reactive protein (CRP).
Horizontal solid lines are medians, and horizontal dotted lines are means.
The boxes show the interquartile ranges. The error bars show the
standard deviations. P-values show the difference between quantiles of
each biomarker using an analysis of variance on the van der Waerden
normal scores.
Figure 2 Median percentage change
from baseline in (A) interferon-c, (B)
interleukin-6, (C) vascular endothelial
growth factor and (D) C-reactive protein.
Table 2 Univariate correlations between biomarker levels (baseline and
percentage change from baseline to week 2 and week 24) and change
from baseline to week 24 in disease activity (BASDAI) and the
inflammation detected by MRI (MRI activity score) in patients with
ankylosing spondylitis who received infliximab 5 mg/kg (n=201) or
placebo (n=78)
Biomarker
Change in MRI activity score Change in BASDAI
Placebo Infliximab Placebo Infliximab
Baseline
IL-6 20.158 20.205*** 0.062 20.258***
VEGF 0.067 20.074 0.140 20.079
CRP 20.047 20.291*** 0.169 20.322***
Percentage change
from baseline to week
2
IL-6 0.080 0.260*** 0.066 0.297***
VEGF 0.110 0.243*** 0.105 0.260***
CRP 0.006 0.296*** 20.017 0.347***
Percentage change
from baseline to week
24
IL-6 20.086 0.215** 0.178 0.340***
VEGF 20.101 0.170* 0.148 0.330***
CRP 20.090 0.243*** 0.147 0.414***
*p,0.05.
**p(0.01.
***p(0.001.
BASDAI, Bath Ankylosing Spondylitis Disease Activity Index; CRP, C-reactive protein;
IL-6, interleukin-6; MRI, magnetic resonance imaging, VEGF, vascular endothelial
growth factor.
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the modulation of inflammatory markers in AS after treatment
with anti-TNF agents and the association with changes in
imaging measures such as MRI has been limited. Data from an
early randomised controlled trial
30 31 and a more recent open-
label study in a small number of patients
32 suggest that baseline
CRP levels may be useful as markers of clinical response after
treatment with infliximab. The results of the current study
represent, to our knowledge, the largest data set of patients
with AS evaluated for inflammatory markers, clinical signs and
symptoms, and the inflammation detected by MRI.
The face validity of inflammatory marker levels was already
evident at baseline. Patients with high baseline IL-6 (.7.38 pg/
ml) and CRP (.1.5 mg/dl) had more spinal inflammation
detected by MRI compared with those with low biomarker
levels. Patients with high baseline CRP levels also had greater
disease activity as measured by BASDAI, and there was a trend
towards greater disease activity for patients with high baseline
IL-6 levels, although the difference was not statistically
significant. Although there was variability in MRI activity and
BASDAI score within each group, the magnitude of the
difference between the groups was greater for MRI activity
compared with BASDAI, suggesting that there may be a
stronger relationship between biomarker levels and spinal
inflammation relative to that between biomarker levels and
disease activity.
Following treatment with infliximab, patients showed
significantly greater reductions in IL-6, VEGF and CRP
compared with patients who received placebo, demonstrating
the discriminant capacity and sensitivity to change of the
biomarkers. These reductions were evident as early as week 2,
and the levels were similarly low at week 24. In line with this
result, treatment with infliximab was shown to modulate
markers of angiogenesis, including VEGF, in synovial tissue
early after initiation of therapy in patients with psoriatic
arthritis.
33
In the infliximab group, baseline IL-6 and CRP levels and
reductions from baseline in IL-6, VEGF and CRP were
significantly correlated with improvement in disease activity
and inflammation at week 24. No significant correlations were
observed in the placebo group. The significance of these
correlations is noteworthy, because a substantial number of
AS patients (about 50%) had undetectable IL-6 levels at
baseline. This finding is consistent with the results of an earlier
pilot study
34 and merits further investigation because there is
limited knowledge on the natural course of IL-6 levels in AS.
The predictive validity of biomarker levels became particu-
larly evident when the clinical response was evaluated. Among
Figure 3 Comparison of the percentage
of ASAS 20 (20% improvement in the
ASsessment in Ankylosing Spondylitis
working group criteria) (A,B) and BASDAI
(Bath Ankylosing Spondylitis Disease
Activity Index) 50 (C,D) responders
between categories of baseline interleukin
(IL)-6 and C-reactive protein (CRP) divided
at the medians.
Table 3 Linear regression modelling of the associations between
biomarker levels (baseline and percentage change from baseline to week
2 or week 24) and change from baseline to week 24 in disease activity
(BASDAI) and the spinal inflammation detected by MRI (MRI activity
score)
Model r
2 b p Value
Infliximab group
MRI activity score: change from baseline to week 24
Baseline biomarker levels
no parameters significantly associated 22 2
Percentage change from baseline to week 2 in
biomarker levels
0.011
IL-6 0.053 ,0.001
Percentage change from baseline to week 24 in
biomarker levels
0.042
CRP 0.009 0.009
BASDAI: change from baseline to week 24
Baseline biomarker levels 0.043
CRP 20.196 0.005
Percentage change from baseline to week 2 in
biomarker levels
0.099
IL-6 0.021 ,0.001
Percentage change from baseline to week 24 in
biomarker levels
0.113
VEGF 0.005 0.029
CRP 0.005 0.005
Placebo group
No biomarker levels at baseline or changes from baseline
to week 2 or 24 were significantly associated with
changes in MRI activity score or BASDAI at week 24
BASDAI, Bath Ankylosing Spondylitis Disease Activity Index; CRP, C-reactive protein;
IL-6, interleukin-6; MRI, magnetic resonance imaging; VEGF, vascular endothelial
growth factor.
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response at week 24 was achieved by a greater percentage of
those with elevated IL-6 or CRP levels at baseline compared
with those with low IL-6 or CRP levels. The multiple regression
analysis enabled us to determine which biomarker was most
associated with spinal inflammation and disease activity. The
results showed that early changes in IL-6 and late changes in
CRP were associated with improvements in both the MRI
activity and the BASDAI score. Baseline CRP levels and
reductions in VEGF levels at week 24 were also associated with
improvements in BASDAI score, but were not associated with
changes in MRI activity score. The finding that early improve-
ment in IL-6 was associated with improvement in both spinal
inflammation and disease activity suggests that IL-6 may play
an earlier and more central role in the inflammatory cascade
than CRP. In this regard, it is noteworthy that IL-6 is thought
to be involved in the initiation of the acute phase response and
the production of CRP in the liver.
35 IL-6 polymorphisms have
been shown to be associated with CRP levels in other
conditions.
89
In the current study, baseline levels of IL-6 and CRP were
generally comparable between both treatment groups. Levels of
serum IL-6 and CRP in previous published studies of patients
with AS have been conflicting; one reporting lower levels than
those in the current study,
36 37 and others reporting higher
levels.
38–40 The reported differences in IL-6 and CRP levels are
most likely related to the heterogeneity of the AS patient
populations studied. In the current study, only patients with
active disease who fulfilled the criteria for anti-TNF therapy
were included. Moreover, IL-6 levels were strongly correlated
with CRP levels at baseline in the current study, which is
consistent with the results of other studies of AS and
rheumatoid arthritis.
38 41 Moderate correlations were observed
between baseline levels of IL-6 and VEGF and between baseline
levels of VEGF and CRP. Treatment with infliximab did not
alter these relationships between the biomarkers. Baseline VEGF
levels in the current study were similar to those previously
reported for patients with early rheumatoid arthritis
42 but were
higher than those of other patients with spondyloarthropa-
thies.
4 In patients with rheumatoid arthritis, IL-6 has been
shown to be a key cytokine in the production of VEGF,
43 and
VEGF may, in turn, stimulate the production of IL-6 and TNF-a
in a positive feedback loop.
44 Our results suggest that similar
relationships between IL-6 and VEGF may play a part in the
inflammation exhibited by some patients with AS. However, as
already stated, a significant number of AS patients had
undetectable levels of circulating IL-6.
Some potential limitations of this study are noteworthy. The
ASSERT study was primarily designed to evaluate the safety
and efficacy of infliximab in patients with AS and was not
powered to evaluate correlations between changes in inflam-
matory markers and clinical measures. In addition, the study
population was somewhat heterogeneous, which included a
range of patients with moderate to severe AS. Finally, the IL-6
assay had limited sensitivity to detect low levels of this
cytokine, and thus, nearly half of the patients had undetectable
IL-6 levels at baseline. This limitation may have resulted in an
underestimation in the strength of the correlations between
changes in IL-6 levels and changes in measures of inflammation
and disease activity in the infliximab group. However, despite
these potential limitations, the results of this study contribute
to our understanding of the importance of IL-6 in the
pathogenesis of AS. The results suggest that the early reduction
of IL-6 may be a critical event in the treatment response and the
pathogenesis of AS. Although biomarker levels were associated
with improvement in disease activity and the spinal inflamma-
tion detected by MRI, their relative contribution to the
explanation of the observed treatment response needs to be
examined further, especially as there is no strong correlation
between BASDAI and MRI (Braun, unpublished). However, the
results of this study do suggest that an early reduction of IL-6
level is important. A reduction in CRP level may have utility as
a surrogate marker of response in clinical practice, especially
given the strong correlation between IL-6 and CRP levels.
MRI has been shown to be a useful tool for evaluating the
reduction in spinal inflammation after anti-TNF therapy, but it
is unclear how early the benefit can be detected. In any case, the
early identification of patients who are most likely to exhibit
improvement through the use of biomarkers will assist
clinicians in their treatment decisions.
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